Cenobamate: First Approval

<div><div>Compliance with Ethical Standards</div><div><br></div><div>Funding The preparation of this review was not supported by any external funding.</div><div><br></div><div>Conflict of interest  During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.</div></div><div><br></div><div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a><br></div><div><br></div><div><p><br></p><p>Abstract</p><p><br></p><p>Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients. This article summarizes the milestones in the development of cenobamate leading to this first approval.</p><p></p><p><br></p><p>© Springer Nature Switzerland AG 2020<br></p><p><br></p><br></div>